Vaxcyte, Inc. SEC filings PCVX
Vaxcyte, Inc. has 767 filings in SEC EDGAR's recent list, going back to Jul 24, 2015. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | Oct 8, 2026 | — |
| 424B5 | Prospectus supplement | Oct 8, 2026 | — |
| FWP | Free writing prospectus | Oct 7, 2026 | — |
| 424B5 | Prospectus supplement | Oct 6, 2026 | — |
| 424B5 | Prospectus supplement | Oct 6, 2026 | — |
| 424B5 | Prospectus supplement | Feb 24, 2026 | — |
| S-8 | Employee stock plan registration | Feb 24, 2026 | — |
| 424B5 | Prospectus supplement | Jan 30, 2026 | — |
| 424B5 | Prospectus supplement | Jan 29, 2026 | — |
| S-8 | Employee stock plan registration | Feb 25, 2025 | — |
| 424B5 | Prospectus supplement | Sep 5, 2024 | — |
| 424B5 | Prospectus supplement | Sep 3, 2024 | — |
| S-3ASR | Automatic shelf registration | May 24, 2024 | — |
| S-8 | Employee stock plan registration | Feb 27, 2024 | — |
| 424B5 | Prospectus supplement | Jan 31, 2024 | — |
| 424B5 | Prospectus supplement | Jan 30, 2024 | — |
| 424B5 | Prospectus supplement | Apr 20, 2023 | — |
| 424B5 | Prospectus supplement | Apr 17, 2023 | — |
| 424B5 | Prospectus supplement | Feb 27, 2023 | — |
| S-8 | Employee stock plan registration | Feb 27, 2023 | — |
| S-3ASR | Automatic shelf registration | Dec 22, 2022 | — |
| 424B5 | Prospectus supplement | Oct 27, 2022 | — |
| 424B5 | Prospectus supplement | Oct 24, 2022 | — |
| S-8 | Employee stock plan registration | Feb 28, 2022 | — |
| 424B5 | Prospectus supplement | Jan 14, 2022 | — |
| 424B5 | Prospectus supplement | Jan 12, 2022 | — |
| S-3ASR | Automatic shelf registration | Jul 2, 2021 | — |
| S-8 | Employee stock plan registration | Mar 29, 2021 | — |
| 424B4 | Prospectus | Jun 15, 2020 | — |
| S-8 | Employee stock plan registration | Jun 12, 2020 | — |
| S-1MEF | Filing | Jun 11, 2020 | — |
| S-1/A | Amended registration statement | Jun 8, 2020 | — |
| S-1 | Registration statement | May 22, 2020 | — |
Showing 33 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PCVX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Carlos, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1649094
- Former names
- SutroVax, Inc. (until Apr 3, 2020)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.